Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1976 1
1977 1
1982 1
1985 1
1987 1
1988 1
1989 1
1990 2
1991 1
1992 1
1993 3
1994 3
1995 1
1996 5
1998 3
1999 6
2000 8
2001 6
2002 2
2003 5
2004 4
2005 2
2006 4
2007 3
2008 8
2009 8
2010 8
2011 16
2012 7
2013 8
2014 8
2015 11
2016 10
2017 13
2018 5
2019 7
2020 14
2021 14
2022 11
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Schüpke S, et al. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475799 Clinical Trial.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. von der Maase H, et al. J Clin Oncol. 2000 Sep;18(17):3068-77. doi: 10.1200/JCO.2000.18.17.3068. J Clin Oncol. 2000. PMID: 11001674 Corrected and republished. Clinical Trial.
Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Georg P, et al. Cell. 2022 Feb 3;185(3):493-512.e25. doi: 10.1016/j.cell.2021.12.040. Epub 2021 Dec 28. Cell. 2022. PMID: 35032429 Free PMC article.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Vedantham S, et al. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066. N Engl J Med. 2017. PMID: 29211671 Free PMC article. Clinical Trial.
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Götz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S. Zwanenburg A, et al. Radiology. 2020 May;295(2):328-338. doi: 10.1148/radiol.2020191145. Epub 2020 Mar 10. Radiology. 2020. PMID: 32154773 Free PMC article.
Black-Si as a Photoelectrode.
Linklater DP, Haydous F, Xi C, Pergolesi D, Hu J, Ivanova EP, Juodkazis S, Lippert T, Juodkazytė J. Linklater DP, et al. Nanomaterials (Basel). 2020 May 1;10(5):873. doi: 10.3390/nano10050873. Nanomaterials (Basel). 2020. PMID: 32369917 Free PMC article.
Low reflectivity R < 5 % of b-Si over the entire visible and near-IR ( lambda < 2 &nbsp; mu m) spectral range was favorable for the better absorption of light, while an increased surface area facilitated larger current densities. ...

Low reflectivity R < 5 % of b-Si over the entire visible and near-IR ( lambda < 2 &nbsp; mu m) spectral range was favorable

…
cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity.
Ventre KS, Roehle K, Bello E, Bhuiyan AM, Biary T, Crowley SJ, Bruck PT, Heckler M, Lenehan PJ, Ali LR, Stump CT, Lippert V, Clancy-Thompson E, Conce Alberto WD, Hoffman MT, Qiang L, Pelletier M, Akin JJ, Dougan M, Dougan SK. Ventre KS, et al. J Immunol. 2023 Apr 1;210(7):991-1003. doi: 10.4049/jimmunol.2200646. J Immunol. 2023. PMID: 36881882 Free PMC article.
Modeling and Simulation of In Vivo Drug Effects.
Lippert J, Burghaus R, Kuepfer L, Ploeger B, Schaller S, Schmitt W, Willmann S. Lippert J, et al. Handb Exp Pharmacol. 2016;232:313-29. doi: 10.1007/164_2015_21. Handb Exp Pharmacol. 2016. PMID: 26578524 Review.
Yet, incomplete investigation of the causality of drug responses is a major risk for translational assessments and the prediction of drug responses in different species or other populations. Mechanism-based modeling and simulation (M&S) offers a means to investigate co …
Yet, incomplete investigation of the causality of drug responses is a major risk for translational assessments and the prediction of drug re …
PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma.
Warmington E, Smith G, Chortis V, Liang R, Lippert J, Steinhauer S, Landwehr LS, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Altieri B, Foster PA, Ronchi CL. Warmington E, et al. Endocr Connect. 2023 Dec 14;13(1):e230403. doi: 10.1530/EC-23-0403. Print 2024 Jan 1. Endocr Connect. 2023. PMID: 37992487 Free PMC article.
NCI-H295R showed a time- and dose-dependent reduction in proliferation with both PLK1i (P< 0.05at 100 nM RGS and 30 M Pol). In MUC-1, a less pronounced decrease was observed (P< 0.05at 1000 nM RGS and 100 M Pol). 100 nM RGS increased apoptosis in NCI-H295R (P& …
NCI-H295R showed a time- and dose-dependent reduction in proliferation with both PLK1i (P< 0.05at 100 nM RGS and 30 M Pol). In MUC …
207 results